SXLV:SW:SW-SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc) (USD)

ETF | Others |

Last Closing

USD 42.51

Change

+0.22 (+0.51)%

Market Cap

N/A

Volume

2.64K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-06 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
CHDIV:SW UBS ETF (CH) - MSCI Switzerlan..

+0.11 (+0.86%)

USD 1,244,681.59B
SWICHA:SW UBS ETF (CH) – MSCI Switzerl..

+0.29 (+1.42%)

USD 226,274.25B
SWUSAH:SW UBS ETF (CH) – MSCI Switzerl..

+0.10 (+0.36%)

USD 226,274.21B
SWEUAH:SW UBS ETF (CH) – MSCI Switzerl..

+0.41 (+1.52%)

USD 226,274.20B
RGLDS:SW Raiffeisen ETF Solid Gold A US..

N/A

USD 134,034.93B
RGLDSH:SW Raiffeisen ETF Solid Gold H CH..

-2.00 (-0.04%)

USD 134,034.91B
RGLDOH:SW Raiffeisen ETF Solid Gold Ounc..

+2.00 (+0.12%)

USD 134,034.86B
RGLDO:SW Raiffeisen ETF Solid Gold Ounc..

+31.50 (+1.39%)

USD 134,034.85B
SPICHA:SW UBS ETF (CH) – SPI® (CHF) A..

+0.81 (+1.09%)

USD 131,872.43B
SPMCHA:SW UBS ETF (CH) – SPI® Mid (CH..

+1.02 (+0.91%)

USD 130,595.12B

ETFs Containing SXLV:SW

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.92% 76% C+ 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.92% 76% C+ 73% C
Trailing 12 Months  
Capital Gain 1.41% 17% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.41% 14% F 19% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 6.16% 58% F 59% D-
Dividend Return 6.16% 58% F 59% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 7.29% 59% D- 63% D
Risk Adjusted Return 84.50% 66% D+ 70% C-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike